Amarin Corp Plc (AMRN)

[yellow_bluff]

Based on this week's 5830 script number, Vascepa only needs steady 2.4pct weekly growth to get to 20k scripts in a year.

Perhaps this cant be done in the Marine only population but who knows exactly where off label is going with Vascepa. With Anchor this seems like a very very low bar to breakeven. assuming 20k scripts is breakeven.

Combine this with the fact that Amarin has already hit up a lot of the docs that are high omega three subscribers so sell into Anchor should be easy w these docs and that Lovaza wont be covered by insurance if Anchor is approved.

This is why GIA is making a lot of sense whether you like it or not.